Cargando…

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

B cells play an important role in the pathogenesis of systemic lupus erythematosus (SLE), so the safety and activity of anti-B cell immunotherapy with the humanized anti-CD22 antibody epratuzumab was evaluated in SLE patients. An open-label, single-center study of 14 patients with moderately active...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dörner, Thomas, Kaufmann, Joerg, Wegener, William A, Teoh, Nick, Goldenberg, David M, Burmester, Gerd R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526638/ https://www.ncbi.nlm.nih.gov/pubmed/16630358 http://dx.doi.org/10.1186/ar1942

Ejemplares similares

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008)

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
por: Steinfeld, Serge D, et al.
Publicado: (2006)

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
por: Daridon, Capucine, et al.
Publicado: (2010)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
por: Al Rayes, Hanan, et al.
Publicado: (2014)

Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells
por: Chang, Chien-Hsing, et al.
Publicado: (2014)

Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus
por: Henneken, Maren, et al.
Publicado: (2005)

Analysis of B-cell subpopulations in systemic lupus erythematosus
por: Dorner, T, et al.
Publicado: (2003)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
por: Wallace, Daniel J, et al.
Publicado: (2014)

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006
por: Strand, Vibeke, et al.
Publicado: (2014)

Targeting CD22 as a strategy for treating systemic autoimmune diseases
por: Dörner, Thomas, et al.
Publicado: (2007)

Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation
por: Sieber, Julia, et al.
Publicado: (2014)

Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis
por: Smith, Michael F, et al.
Publicado: (2009)

Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling
por: Giltiay, Natalia V., et al.
Publicado: (2017)

Lupus nephropathy as the initial manifestation of systemic lupus erythematosus.
por: Lynn, R. I., et al.
Publicado: (1980)

LUPUS PANNICULITIS AS AN INITIAL MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS
por: Patel, Raksha M, et al.
Publicado: (2010)

Lupus Enteritis as an Initial Presentation of Systemic Lupus Erythematosus
por: Sran, Sisira, et al.
Publicado: (2014)

Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients
por: Fleischer, Vanessa, et al.
Publicado: (2015)

Cricoarytenoiditis as an Initial Manifestation of Systemic Lupus Erythematosus
por: Hougardy, Jean-Michel, et al.
Publicado: (2011)

Meningitis as the initial manifestation of systemic lupus erythematosus
por: Al Mahmeed, Nada, et al.
Publicado: (2020)

Chemosis as an Initial Presentation of Systemic Lupus Erythematosus
por: Luceno, Carvy Floyd, et al.
Publicado: (2022)

TEN Like Lupus: A Rare Initial Presentation of Lupus Erythematosus
por: Kumar, Richa, et al.
Publicado: (2022)

B cells, BAFF/zTNF4, TACI, and systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2001)

Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus
por: Robinson, Sean, et al.
Publicado: (2021)

Toll-like receptor signalling in B cells during systemic lupus erythematosus
por: Fillatreau, Simon, et al.
Publicado: (2020)

Acute Pancreatitis as the Initial Presentation of Systematic Lupus Erythematosus
por: Jia, Yi, et al.
Publicado: (2014)

Embolic Stroke as the Initial Manifestation of Systemic Lupus Erythematosus
por: Khan, Reshma M., et al.
Publicado: (2015)

Alveolar hemorrhage as the initial presentation of systemic lupus erythematosus
por: de Holanda, Bruna A., et al.
Publicado: (2016)

Cardiogenic shock as the initial manifestation of systemic lupus erythematosus
por: Liu, Liang, et al.
Publicado: (2020)

Constrictive Pericarditis as an Initial Manifestation of Systemic Lupus Erythematosus
por: Gupta, Samiksha, et al.
Publicado: (2020)

Hypoparathyroidism as one of the initial presentations of systemic lupus erythematosus
por: Gadakchi, Leyla, et al.
Publicado: (2022)

Lupus Panniculitis as an Initial Manifestation of Systemic Lupus Erythematosus: A Case Report
por: Zhao, Yu-Kun, et al.
Publicado: (2016)

An Elderly Gentleman with Acute Lupus Pneumonitis as the Initial Manifestation of Systemic Lupus Erythematosus
por: Ferrero, Gina, et al.
Publicado: (2021)

Lupus Cerebritis as the Initial Presentation of Systemic Lupus Erythematosus in a Young Female
por: Gosal, Kiranpreet, et al.
Publicado: (2021)

Discoid lupus erythematosus precipitated by topical diphencyprone immunotherapy for alopecia areata
por: Foo, Hui Ling, et al.
Publicado: (2020)

The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression
por: Frölich, Daniela, et al.
Publicado: (2012)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6h71897km9c2r4fh0gsp9ovapv